Gain Therapeutics to Attend the 2025 Maxim Growth Summit
Gain Therapeutics, Inc. (GANX)
Company Research
Source: GlobeNewswire
BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it will participate in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC. Gene Mack, President and CEO of Gain, will be participating in a live discussion, “Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutics Categories”, on October 22nd. The panel will include discussion about innovative approaches for a range of neurogenerative diseases that are in active clinical trials, If you are interested in meeting with Gain management, please contact your Maxim sales representative to schedule. About the Maxim Growth Summit This event brings together industry leaders, innovators, and premier institutions to explo
Show less
Read more
Impact Snapshot
Event Time:
GANX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GANX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GANX alerts
High impacting Gain Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GANX
News
- Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development [Yahoo! Finance]Yahoo! Finance
- Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025GlobeNewswire
- Gain Therapeutics GAAP EPS of -$0.15 beats by $0.01 [Seeking Alpha]Seeking Alpha
- Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate UpdateGlobeNewswire
GANX
Sec Filings
- 12/3/25 - Form S-8
- 11/28/25 - Form 8-K
- 11/28/25 - Form 424B5
- GANX's page on the SEC website